Table 1.
Correlation between LOXL2 and different clinicopathological features.
| Characteristic | Low-expression of LOXL2 | High-expression of LOXL2 | p |
|---|---|---|---|
| n | 187 | 187 | |
| Age, n (%) | 0.107 | ||
| ≤ 60 | 80 (21.4%) | 97 (26%) | |
| > 60 | 106 (28.4%) | 90 (24.1%) | |
| Gender, n (%) | 0.027 | ||
| Female | 50 (13.4%) | 71 (19%) | |
| Male | 137 (36.6%) | 116 (31%) | |
| Race, n (%) | 0.188 | ||
| Asian | 81 (22.4%) | 79 (21.8%) | |
| Black or African American | 12 (3.3%) | 5 (1.4%) | |
| White | 88 (24.3%) | 97 (26.8%) | |
| T stage, n (%) | 0.013 | ||
| T1 | 101 (27.2%) | 82 (22.1%) | |
| T2 | 49 (13.2%) | 46 (12.4%) | |
| T3 | 33 (8.9%) | 47 (12.7%) | |
| T4 | 2 (0.5%) | 11 (3%) | |
| N stage, n (%) | 0.125 | ||
| N0 | 121 (46.9%) | 133 (51.6%) | |
| N1 | 0 (0%) | 4 (1.6%) | |
| M stage, n (%) | 1.000 | ||
| M0 | 130 (47.8%) | 138 (50.7%) | |
| M1 | 2 (0.7%) | 2 (0.7%) | |
| Pathologic stage, n (%) | 0.121 | ||
| Stage I | 96 (27.4%) | 77 (22%) | |
| Stage II | 44 (12.6%) | 43 (12.3%) | |
| Stage III | 34 (9.7%) | 51 (14.6%) | |
| Stage IV | 2 (0.6%) | 3 (0.9%) | |
| Histologic grade, n (%) | 0.029 | ||
| G1 | 37 (10%) | 18 (4.9%) | |
| G2 | 87 (23.6%) | 91 (24.7%) | |
| G3 | 54 (14.6%) | 70 (19%) | |
| G4 | 7 (1.9%) | 5 (1.4%) | |
| Tumor status, n (%) | 0.305 | ||
| Tumor free | 106 (29.9%) | 96 (27%) | |
| With tumor | 71 (20%) | 82 (23.1%) |